- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging (MRI)
- Drug · Procedure
- Lead sponsor
- Zhen Wang, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–33
of 33
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma Multiforme (GBM)
- Interventions
- Hyperpolarized 13C Pyruvate
- Drug
- Lead sponsor
- Susan Chang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glioma
- Interventions
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Radiation Therapy, Chemotherapy
- Radiation · Procedure · Drug
- Lead sponsor
- Susan Chang
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
- Interventions
- Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
- Other · Drug · Procedure
- Lead sponsor
- Daniel M. Spielman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Prostate Cancer
- Interventions
- Hyperpolarized 13C-Pyruvate
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 40 Years to 80 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
- Interventions
- Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Fatty Liver
- Interventions
- MRI Tracer
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- High Risk Prostate Carcinoma, Prostate Cancer
- Interventions
- Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Ivan de Kouchkovsky, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glioma
- Interventions
- Hyperpolarized 13C-Pyruvate
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland